NetraMark Initiates AI-Driven Collaboration in Glioblastoma Research

Rhea-AI Summary

NetraMark Holdings (OTCQB: AINMF) has announced a strategic collaboration to advance glioblastoma (GBM) research using its NetraAI platform. The company has secured access to clinical and biomarker datasets from a leading U.S. academic medical center to develop therapeutic decision support tools for future GBM trials.

The collaboration will analyze longitudinal cerebrospinal fluid (CSF) proteomic datasets through six key objectives, including distinguishing GBM samples, differentiating tumor types, and studying disease recurrence patterns. The project aims to address the challenges in GBM treatment, where clinical trials face a 90% failure rate and patients have a median survival of just 15 months.

Positive

• Access to proprietary clinical and biomarker datasets from a leading U.S. academic medical center
• Application of NetraAI platform to identify patient subgroups and optimize trial enrichment strategies
• Comprehensive analysis approach covering six distinct research objectives in GBM treatment
• Potential to improve clinical trial success rates in a field with 90% failure rate

Negative

• Complex research project with no guaranteed success in improving trial outcomes
• Challenging disease area with historically poor patient outcomes (15-month median survival)
• Multiple variables and complex data analysis required for meaningful results

TORONTO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced a new collaboration focused on glioblastoma (GBM) research. The collaboration, supported by a license to proprietary know-how, grants NetraMark access to clinical and biomarker datasets from a leading U.S. academic medical center.

NetraAI, the Company’s explainable AI platform, will be applied to these datasets to identify patient subgroups to help build a therapeutic decision support tool that can be used to inform future GBM trials.

Glioblastoma is an aggressive and difficult-to-treat cancer, with median survival of just 15 months and fewer than 7% of patients surviving beyond five years. Clinical trials in GBM have a failure rate exceeding 90%, often due to heterogeneous patient populations, limited predictive biomarkers, and poorly defined inclusion criteria.

Project Objectives

NetraMark’s analysis under the collaboration will focus on generating novel insights and hypotheses from longitudinal cerebrospinal fluid (CSF) proteomic datasets. NetraAI will analyze the data into explainable and unexplainable subpopulations, seeking to deliver insights in the form of NetraPersonas—collections of patients, variables, and statistical evidence that can be leveraged to optimize future trial enrichment strategies.

The specific objectives include:

• Glioma vs. Non-Tumor Controls – Identify markers distinguishing GBM samples
• Glioma vs. Non-Glioma Brain Tumors – Differentiate GBM from supratentorial brain metastases to refine glioma-specific biomarkers.
• Disease Recurrence – Contrast primary and recurrent gliomas to identify molecular markers of recurrence and tumor evolution.
• Impact of Resection – Evaluate paired pre- and post-surgical resection samples to understand molecular changes from surgery.
• Impact of Chemoradiation – Analyze paired pre- and post-treatment samples to assess therapy response and resistance mechanisms.
• Impact of Immunotherapy – Explore pre- and post-immunotherapy lumbar CSF samples to identify molecular effects of immunotherapy.

Data and Resources

The academic partner will provide expanded longitudinal glioblastoma proteomic datasets generated on the SomaLogic platform, along with related de-identified materials.

This collaboration represents an important opportunity in applying explainable AI to a significant challenge in oncology, with the potential to help trial sponsors design more efficient, targeted, and successful glioblastoma studies.

“We are excited to collaborate with a leading academic medical center on this challenging area of oncology,” said Josh Spiegel, President of NetraMark. “By applying NetraAI to high-quality glioblastoma datasets, we aim to identify explainable patient subgroups that can guide treatment strategies, accelerate biomarker discovery, and support the design of more successful clinical trials.”

About NetraAI
In contrast to other AI-based methods, NetraAI is uniquely engineered to include focus mechanisms that separate small datasets into explainable and unexplainable subsets. Unexplainable subsets are collections of patients that can lead to suboptimal overfit models and inaccurate insights due to poor correlations with the variables involved. The NetraAI uses the explainable subsets to derive insights and hypotheses (including factors that influence treatment and placebo responses, as well as adverse events) providing the potential to increase the chances of a clinical trial success. Many other AI methods lack these focus mechanisms and assign every patient to a class, often leading to "overfitting" which drowns out critical information that could have been used to improve a trial's chance of success.

About NetraMark
NetraMark is a company focused on being a leader in the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.

For further details on the Company please see the Company’s publicly available documents filed on the System for Electronic Document Analysis and Retrieval+ (SEDAR+).

Forward-Looking Statements

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation including statements regarding the Company's primary objectives under the Collaboration Agreement to evaluate data which aims to provide oncologists with tools to identify biologically meaningful GBM subgroups that may respond differently to investigational therapies and potentially help trial sponsors design more efficient, targeted, and successful glioblastoma studies, which are based on NetraMark's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results of the Company or industry results to differ materially from future results, performance or achievements. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, NetraMark does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for NetraMark to predict all such factors.

When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements as set out in the materials we file with applicable Canadian securities regulatory authorities on SEDAR+ at www.sedarplus.ca including our Management’s Discussion and Analysis for the year ended September 30, 2024. These risk factors and other factors could cause actual events or results to differ materially from those described in any forward-looking information.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Contact Information:
Swapan Kakumanu - CFO | swapan@netramark.com | 403-681-2549

FAQ

What is the purpose of NetraMark's (AINMF) collaboration in glioblastoma research?

NetraMark will use its NetraAI platform to analyze clinical and biomarker datasets to identify patient subgroups and build therapeutic decision support tools for future GBM trials, aiming to improve trial success rates.

What are the main objectives of NetraMark's glioblastoma research project?

The project has six main objectives, including distinguishing GBM samples, differentiating tumor types, analyzing disease recurrence, and studying the impacts of resection, chemoradiation, and immunotherapy.

What is the current success rate of glioblastoma clinical trials?

Glioblastoma clinical trials currently have a failure rate exceeding 90%, largely due to heterogeneous patient populations, limited predictive biomarkers, and poorly defined inclusion criteria.

What is the survival rate for glioblastoma patients?

Glioblastoma patients have a median survival of 15 months, with fewer than 7% of patients surviving beyond five years.

How will NetraMark analyze the glioblastoma data?

NetraMark will use its NetraAI platform to analyze longitudinal cerebrospinal fluid proteomic datasets into explainable and unexplainable subpopulations, creating NetraPersonas for optimizing trial enrichment strategies.